A bioactive peptide from the frog skin secretion of Pelophylax nigromaculatus GAPKGCWTKSYPPKPCS-NH2 by Chen, Yutong
School of Pharmacy
Faculty of Medicine, Health and Life Science
A bioactive peptide from the frog skin











Chapter 1 Introduction................................................................................................... 1
1.1 Amphibians................................................................................................................1
1.1.1 Evolutionary history of amphibian....................................................................2
1.1.2 Classification of amphibian...............................................................................3
1.1.3 Amphibian skin and skin secretions..................................................................3
1.2 Protease Inhibitors................................................................................................... 4
1.2.1 The Families of Protease Inhibitors.................................................................. 5
1.2.2 Kazal-type Protease Inhibitors.......................................................................... 6
1.2.2.1 Kazal-type Inhibitor Structure..........................................................6
1.2.2.2 Mechanism of Kazal-type Inhibition................................................8
1.2.3 Kunitz-type Protease Inhibitors.........................................................................8
1.2.3.1 Kunitz-type Inhibitor Structure........................................................ 9
1.2.3.2 Mechanism of Kunitz-type Inhibition............................................ 10
1.2.4 Bowman-Birk-type Protease Inhibitors...........................................................10
1.2.4.1 Bowman-Birk-type Inhibitor Structure.......................................... 11
1.2.4.2 Mechanism of Bowman-Birk-type Inhibition................................ 12
1.3 Aims and Objectives..............................................................................................12
III
Chapter 2 Materials and Methods............................................................................... 14
2.1 Molecular Cloning and Sequencing........................................................................ 14
2.1.1 Acquisition of Skin Secretion from Pelophylax nigromaculatus................... 15
2.1.2 mRNA Isolation.............................................................................................. 15
2.1.3 cDNA Library Construction............................................................................16
2.1.4 RACE Polymerase Chain Reaction (PCR)..................................................... 18
2.1.4.1 Rapid Amplification of cDNA Ends (RACE)................................ 18
2.1.4.2 Agarose Gel Electrophoresis of RACE PCR Products...................19
2.1.4.3 PCR Product Purification............................................................... 20
2.1.5 Recombinant Plasmid DNA............................................................................20
2.1.5.1 Ligation of Interested DNA with pGEM®-T Easy Vector............ 20
2.1.5.2 Transformation of the Recombinant Plasmid DNA....................... 21
2.1.5.3 Isolation of Recombinant Plasmid DNA from JM109 E.coil
Cells............................................................................................................22
2.1.6 Cloning PCR................................................................................................... 23
2.1.6.1 Cloning PCR of the DNA of Interest............................................. 23
2.1.6.2 Agarose Gel Electrophoresis of Cloning PCR Products................ 24
2.1.6.3 Purification of Cloning PCR Products........................................... 24
2.1.7 DNA Sequencing............................................................................................ 24
2.1.7.1 Sequencing Reaction...................................................................... 24
2.1.7.2 Purification of Extension Products.................................................25
IV
2.1.7.3 Sanger Sequencing......................................................................... 26
2.2 Solid Phase Peptide Synthesis (SPPS)...................................................................26
2.2.1 Calculating and Weighting..............................................................................27
2.2.2 Prepared the Stock Solution in the Solvent Bottles........................................ 28
2.2.3 Peptide Synthesizing by Tribute Synthesizer..................................................29
2.2.4 Cleavage and Deprotection of Peptide............................................................30
2.2.5 Washing and Lyophilisation........................................................................... 30
2.3 Peptide Purification by RP-HPLC......................................................................... 31
2.4 MALDI-TOF Mass Spectrometry Analysis.......................................................... 32
2.5 Bioactive Assays....................................................................................................32
2.5.1 Trypsin Inhibitory Assay.................................................................................32
2.5.2 Antimicrobial Assay........................................................................................33
2.5.2.1 Minimum Inhibitory Concentration (MIC) Assays........................34
2.5.2.2 Minimum Bactericidal Concentration (MBC) Assays................... 34
2.5.3 Anticancer Cell Activity Assay.......................................................................35
2.5.3.1 Resuscitation of Frozen Cell Lines.................................................35
2.5.3.2 Cell Subculture and Passage...........................................................35
2.5.3.3 Cell Quantification......................................................................... 36
2.5.3.4 Cell Seeding....................................................................................36
2.5.3.5 Cell Starvation................................................................................ 37
2.5.3.6 Peptide Preparation.........................................................................37
V2.5.3.7 Peptide loading............................................................................... 37
2.5.3.8 MTT assay...................................................................................... 37
2.5.4 Haemolysis assay............................................................................................ 38
2.5.4.1 Horse blood preparation................................................................. 38
2.5.4.2 Calculations and peptide dilution................................................... 38
2.5.4.3 96-well-plate haemolysis assay...................................................... 39
Chapter 3 Results.......................................................................................................... 40
3.1 Molecular cloning of peptide QUB-1804 precursor encoding cDNA.....................40
3.2 RP-HPLC chromatography analysis and MALDI-TOF molecular weight
determination of the crude synthetic peptide QUB-1804............................................ 43
3.3 Physicochemical properties and secondary structure prediction of QUB-1804.... 47
3.4 Trypsin Inhibitor Activity of QUB-1804...............................................................48
3.5 Antimicrobial Activity of QUB-1804....................................................................51
3.6 MTT cell proliferation assay of QUB-1804.......................................................... 52
3.7 Haemolytic Activity of QUB-1804........................................................................54
Chapter 4 Discussion.....................................................................................................56





Herein, I really appreciate my supervisor Prof. Chris Shaw, Dr. Tianbao Chen, Dr.
Lei Wang, Dr. Mei Zhou, Dr. Xinping Xi and Dr. Chengbang Ma for granting me
such a great opportunity to investigate significant project in terms of naturally-
occurring bioactive peptides among anuran amphibians.
Additionally, my completion of this work could not have been accomplished without
the support of my colleagues in the laboratory. I would like to thank you for always
caring for me and sharing knowledge and information with me on the topic.




I declare that the research reported in this thesis is my own work except where
acknowledgement has been made. All work was carried out in the School of
Pharmacy, Faculty of Medicine, Life and Health Sciences, Queen’s University,
Belfast.
I hereby declare that for 5 years following the date on which the thesis is deposited in
the Library of Queen’s University, Belfast, the thesis shall remain confidential with
access or copying prohibited. Following expiry of the period I permit the librarian of
the University to allow the thesis to be copied in whole or in part without reference
to me on the understanding that such authority applies to the provision of single
copies made for study purposes or for inclusion within the stock of another library.
This restriction does not apply to the British Library Thesis Service.
It is a condition of use of this thesis that anyone who consults it must recognize that
the copyright rests with the author and that no quotation from the thesis and no




In this study, we describe a synthesized peptide with C-terminally amidated,
GAPKGCWTKSYPPKPCS-amide that contains a disulphide loop between Cys6 and
Cys16 that is consistent with a Bowman–Birk type protease inhibitor, from the skin
secretion of the frog Pelophylax nigromaculatus. The precursor was obtained from
the Pelophylax nigromaculatus skin secretion by employing molecular cloning. The
corresponding mature peptide, namely QUB-1804, was identified by bioinformatic
approach from this cloned biosynthetic precursor-encoding cDNA sequence.
Subsequently, the chemically-synthesised replicate was subjected to a series of
bioassays. It was found that QUB-1804 is a Bowman-Birk-type protease inhibitor
which belongs to ranacyclin family. It has respectively trypsin inhibitory activity
with Ki value of 0.373 µM. But QUB-1804 does not possess significant
antimicrobial activity on three model micro-organisms: Gram-positive bacterium (S.
aureus), Gram-negative bacterium (E. coli) and an opportunistic yeast bacterium (C.
albicans). Additionally, this peptide failed to inhibit the proliferation of cancer cell
this peptide towards PC-3, H157, U251MG and MCF-7 cancer cell lines at the
challenge concentration of 10-5 M. Meanwhile, this peptide showed, there is no
significant haemolysis when the concentration is lower than 256 µM. These data





The word ‘amphibian’ is derived from the Ancient Greek term ἀμφίβιος (amphíbios),
which represents ‘living a double life’. Amphibians are cold-blooded vertebrates
belonging to the class Amphibia. They evolved from fish, and with the long-term
evolution allows amphibians to live both in the water and on land. The larvae live in
the water, breathe with the gills, while they grow up they breathe through the lungs
as well as the skin. Amphibians have bare skin, hair, no scales on the surface (except
for some crichtones), but mucus can be secreted to keep the body moist.
1.1.1 Evolutionary history of amphibian
Amphibian descendants of lobe-finned fishes which had a high similarity to lungfish
and coelacanth in the modern world. They were first found in the Devonian periods,
some 300-350 million years ago, experienced a complex evolutionary adaptation
process because of the extremely hard environment during the Devonian periods
(Buckley and Jetz, 2007). Due to the low oxygen in the water, these ancient lobe-
finned fish had to develop lungs function in order to help them breathe air, but still
mainly use gills to breathe. They even let themselves out of water and emerged on
dry land with the help of their powerful fins. Finally, their fins evolved into four legs
which can help them crawl on land. These four-legged animals were the ancestors to
all tetra pods. During the Carboniferous period they developed the skill that they can
walk on land. With the transition from aquatic to terrestrial habitats, they generated
‘feet’ and ‘hands’ according to five or more digits, their skeletons became stronger in
order to hold their body on land, their lungs’ function had developed. This evolve
adaptation help amphibian to stay on land for a long period for nearly 75 million
years (Ahlberg and Clack, 2006).
31.1.2 Classification of amphibian
Three orders are existing in modern amphibian: Gymnophiona/Apoda (the
caecilians), Caudata/Urodela (the salamanders) and Anura (frogs and toads) (Zhou et
al., 2006). These three orders of living amphibian make up subclass Lissamphibia.
They have different structural appearance. Salamanders are smaller than the other
two orders in terms of body shape, but they have tails and two pairs of limbs of
roughly the same size. Caecilians look like a earthworms and do not have tail. Frogs
and toads do not have tail and use their strong hint to leap (Stebbins and Cohen,
1997).
1.1.3 Amphibian skin and skin secretions
Amphibian skin is an important organ because it plays an important role in the
survival of amphibians. Skin is a respiratory organ for amphibians. When amphibians
are in the water, they can use their skins to breathe. Besides, it provides an avenue
for water to exchange other materials (Wells, 2010).
It contains two layers: the thick inner dermis and the thin outer epidermis. Generally,
amphibian has two kinds of intergumentary glands, poison (granular or serous)
glands and mucous glands. Poison glands produce toxins or poisons to provide
protection against fungal and bacterial infection as well as to defend against
predators while mucous glands are used to help the amphibian skin moist and
slippery skin surface because they can keep water balance (Dapson et al., 1973,
Toledo and Jared, 1995, Çevikbaş, 1978). The secretions of frog skins are considered
to have a particularly rich natural resources (Clarke, 1997). The diversity of
compounds released by granular glands of amphibians is surprisingly high.
4Amphibian skin secretion components can be divided into four main parts: steroids,
alkaloids, biogenic amines and peptides and proteins (Clarke, 1997).
1.2 Protease Inhibitors
Proteases, also known as proteolytic enzymes, are widely isolated and characterized
from plants, animals and microorganisms (Joanitti et al., 2006, Christeller, 2005). In
their target proteins, proteases can cleavage the specific peptide bonds. Protease
inhibitors can be divided into five major groups, active sites with cysteine (C) and
aspartate (D) residues are associated with the intracellular proteolysis based on
lysosomes while active sites with threonine (T) and serine (S) are associated with
extracellular proteolysis and metal ions. Naturally occurring protease inhibitors are
crucial for regulating the activity of their relevant proteases and also play an
important role in regulatory function in many biological processes. Other functions
besides blocking protease action have also been found for some protease inhibitors.
For example, involvement in carcinogenesis, receptor clearance signalling and
growth factor activities (QI et al., 2005).
Serine proteases and their related inhibitors have been studied in the most detail.
They are of broad interest because they play some key roles in biological
fundamental processes such as inflammation, blood coagulation, complement
fixation and peptide hormone release. At the same time, they constitute pathogenic
factors in some diseases including cancer, inflammation, fibrinolysis and pulmonary
emphysema (Drag and Salvesen, 2010, Wang et al., 2012a, Ivanov et al., 2006).
Trypsin is a typical serine protease found in the digestive system. Trypsin needs
proteolytic processing to be activated in order to synthesis as trypsinogen. When the
carboxyl functional site of the activated trypsin has lysine or arginine, they act only
specifically on peptide bonds. Due to the protein inhibitor of the activated form and
5its interaction with antitrypsin, further examination of the activity of trypsin can be in
progress (Qasim et al., 1999).
1.2.1 The Families of Protease Inhibitors
According to the relationship of the inhibitory domains and the relationship of
sequence, protease inhibitors can be divided into families and subfamilies. An
inhibitor domain represents the portion of the amino acid sequences consisting a
single reactive site. According to the relationship of their inhibitor domains, protease
inhibitor can be classified into 67 families (Rawlings et al., 2004). Simple inhibitors
represent proteins having a single inhibitor domain while complex inhibitors
represent proteins containing multiple inhibitor domains. Eleven families are
grouped to the complex inhibitors with 2-15 inhibitory domains. Most complex
inhibitors are homotypic with inhibitor units from a single family, however some are
heterotypic with inhibitor units from various families (Richardson et al., 2001,
Trexler et al., 2001, Trexler et al., 2002). Here, we describe three representative
families including Kazal-type Kunitz-type and Bowman-Birk-type protease
inhibitors (Table 1.1).
Table 1.1. Families of protease inhibitors with some representative type examples.
Family or
Subfamily
Common Name Type example and Source
I1 Kazal ovomucold unit 3 (Meleagris gallopavo)
I2 Kunitz (animal) aprotinin (Bos Taurus)
I3 (A) Kunitz (plant) soybean trypsin inhibitor (Glycine max)
6I12 Bowman-Birk Bowman–Birk trypsin inhibitor unit 1
(Glycine max)
1.2.2 Kazal-type Protease Inhibitors
Kazal-type protease inhibitors are widely found in the vertebrates and invertebrate
species such as avian, mammals, blood-sucking insects, shrimp, snail, etc.
(Laskowski Jr and Kato, 1980). Based on sequence homologies, Kazal-type
inhibitors can form an independent family. The Kazal-type inhibitors are classified
into the I1 family peptidase inhibitors. This family was named after the first isolate
of pancreatic secretory trypsin by Kazal et al. (Kazal et al., 1948). Some Kazal-type
inhibitors are likely to protect the host from microbial proteinases while some
protease from the parasitic protozoa help to protect the parasites from the host
digestive proteinase enzymes (Visetnan et al., 2009).
1.2.2.1 Kazal-type Inhibitor Structure
The invertebrate Kazal-type protease inhibitors have one or more protein domains
with single or multiple Kazal-type protease inhibitory domains linked together and
their length are variable. There are 40–60 amino acid residues in a canonical Kazal
domain. In general, the vertebrate Kazal domain architecture is similar as
invertebrate domain architecture, but vertebrate Kazal domain is slightly larger than
the invertebrate domain (Rimphanitchayakit and Tassanakajon, 2010). Kazal-type
inhibitors are characterized by a classical disulphide loop between their cysteine
residues (Laskowski Jr and Kato, 1980). In the Kazal-type protease inhibitory
domains, three disulphide bonds can be formed between cysteine 1-5, 2-4 and 3-6
7with the appearance of six conserved cysteine. The three-dimensional structure is
shown as Figure 1.1.
Figure 1.1. The structure of Kazal-type protease inhibitor from vertebrate and
invertebrate. The structure of a typical vertebrate Kazal-type protease inhibitor (A)
with its covalent primary structure (C). The structure of a representative invertebrate
Kazal-type protease inhibitor (B) with its covalent primary structure (D). The space-
filled side chains of the P1 amino acids are in orange colour. The yellow balls
represent the sulphur atoms. Red and blue represent helices and sheets respectively
(Krowarsch et al., 2003).
81.2.2.2 Mechanism of Kazal-type Inhibition
There is a standard mechanism of Kazal-type protease inhibitory that inhibit
proteases (Laskowski Jr and Kato, 1980). Kazal-type domains perform as the
substrate analogue, which binds to the active site of the cognate protease
competitively by its conserve reactive site loop. And it can form a proteinase-
proteinase inhibitor complex. This complex is much more stable compare to the
Michaelis enzyme-substrate complex. The inhibition is very strong because the
binding is very tight and the association constant is very high (Li et al., 2009). The
P1 amino acid residues play the most important role in inhibition specificity, while
other positions’ amino acid residues also influence specificity of the serine protease
inhibitors for their cognate proteases as well as the binding efficacy (Campos et al.,
2004, Lu et al., 2001).
1.2.3 Kunitz-type Protease Inhibitors
Kunitz-type protease inhibitors are widely found in animal, plant and microorganism
sources such as cereals human urine, snakes and soybeans (Ishikawa et al., 1994,
Laskowski Jr and Kato, 1980). Based on sequence homologies, Kunitz-type
inhibitors can form an independent family. Animal Kunitz-type proteins were
classified into the I2 family peptidase inhibitors while plant Kunitz-type proteins are
grouped into the I3 (A) family peptidase inhibitors (Rawlings et al., 2004,
Ranasinghe and McManus, 2013). Kunitz-type protease inhibitors are mainly inhibit
serine proteases like trypsin and chymotrypsin (Laing and McManus, 2002). Kunitz-
type protease inhibitors involved in inhibit serine protease activity and also play a
key role in anti-inflammatory activity (Shigetomi et al., 2010).
91.2.3.1 Kunitz-type Inhibitor Structure
The Kunitz-type protease inhibitors have single or multiple protein domain with
single or multiple Kunitz-type protease inhibitory domains linked together. The first
described Kazal-type protease inhibitor is Bovine pancreatic trypsin inhibitor (BPTI).
BPTI is a representative Kunitz-type inhibitor with single domain (Kunitz and
Northrop, 1936). Ancylostoma caninum (hookworm) Kunitz-type inhibitor have 12
domains. There are around 60 amino acid residues in a canonical Kunitz-type domain.
Kunitz-type inhibitors are characterized by a conserved loop between their cysteine
residues and stabilized by three disulphide bridges between cysteine 1-6, 2-4 and 3-5
(Laskowski Jr and Kato, 1980). The structure of a Kunitz-type protease inhibitor is
shown in Figure 1.2.
Figure 1.2. The folding structure of Kunitz-type protease inhibitor showing three
disulphide bridge forming by six cysteine amino acid residues (Laskowski Jr and
Kato, 1980).
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1.2.3.2 Mechanism of Kunitz-type Inhibition
There is a standard mechanism of Kunitz-type protease inhibitory that inhibit
proteases which related to a non-covalent and tight interaction just like the substrate-
enzyme Michaelis complex. There is no conformational change when Kunitz-type
protease inhibitors block active site of serine protease. At the same time, anti-parallel
β-sheet can be formed between inhibitors and enzymes (Ranasinghe and McManus,
2013). The part which responsible for the inhibition of protease is termed the
protease-binding loop. Among the protease-binding loop, P1-P1’ reactive site is sited
in the most exposed part. The P reactive site at N-terminal side play an important
role in inhibition specificity, and it is more important than the C-terminal side P’
reactive site (Perona and Craik, 1997). The position P1 amino acid residues play the
most important role in inhibition specificity by Kunitz-type inhibitors, while the
position P1’ also affect the protein–protein association energy (Krowarsch et al.,
1999).
1.2.4 Bowman-Birk-type Protease Inhibitors
There are many sources of Bowman-Birk inhibitors (BBI), while it was first isolated
from soybean by Bowman (Bowman, 1946) and characterized by Birk, and then
Bowman-Birk inhibitor was named after this two scientists (Losso, 2008). Based on
the sequence homologies, Bowman-Birk-type inhibitors can form an independent
family which is grouped into the I12 family peptidase inhibitors (Rawlings et al.,
2004). BBI consisted of 16 amino acid residues extension at N-terminals were
biosynthesized (Losso, 2008, Joudrier et al., 1987, Al‐Wesali et al., 1995). The
cDNA cloning strategy encoding the Bowman-Birk protease inhibitors have been
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applied. The nucleotide sequence homology between these clones is very high and
the two reaction domains in each clone is also very high (Baek et al., 1994).
1.2.4.1 Bowman-Birk-type Inhibitor Structure
The primary structure of Bowman-Birk-type inhibitor is shown in Figure 1.3. BBI
contains 71 amino acid residues with seven disulphide bonds between cysteine 9-24,
14-22, 8-62, 12-58, 36-51, 32-39 and 41-49. The seven disulphide bridges are related
to the stability of the enzyme hydrolysis and protein molecule towards acid. The
conserved cysteine proteins are responsible for the high homology of the amino acid
sequence and help to maintain a rigid structure (Losso, 2008). Most Bowman-Birk-
type inhibitors have a ‘double headed’ structure with two tricyclic domains. Each
domain contains an independent ‘canonical’ proteinase binding site and one inhibitor
molecule can form a 1:1:1 stoichiometric complex with two different proteinases
(Song et al., 1999).
.
Figure 1.3. The structure of Bowman-Brik-type protease inhibitor. The disulfide
bridge are shown in black colour and the active sites are also indicated in black
colour (Song et al., 1999).
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1.2.4.2 Mechanism of Bowman-Birk-type Inhibition
There is a standard mechanism of Bowman-Birk-type protease inhibitory that inhibit
proteases (Laskowski Jr and Kato, 1980). The position P1 amino acid residue plays
the most important role and the amino acid residue at the P1 position is thought to
have the most important role in the specificity and proteinases inhibitory activity
(Laskowski Jr and Kato, 1980, Qasim et al., 1997). BBI mainly inhibit trypsin and
chymotrypsin. When the amino acid residues at P1 position are arginine or lysine, it
can inhibit trypsin, while the amino acid residues at P1 position are Leu, Met, Tyr,
Phe or Trp, it can inhibit chymotrypsin (Odani and Ono, 1980). The trypsin
inhibitory activity of Bowman-Birk-type inhibitor is related to two subdomains
within Ser17-Lys16 and Leu43-Ser44. The mechanism of trypsin inhibition is
responsible for the lysine amino acid residue while chymotrypsin inhibition involves
the interaction of Leu43 or Ser44 with chymotrypsin active site (Kumar et al., 2002).
During trypsin inhibition, the Lys16 of the BBI molecule extends into the primary
pocket of trypsin forming a direct network of two hydrogen bonds to Asp189 therefore
blocking the active site of trypsin (Voss et al., 1996).
1.3 Aims and Objectives
● cDNA Library in the skin secretion of the frog (Pelophylax nigromaculatus) will
be constructed according to use SMART (switching mechanism at 3’ end of RNA
transcript) strategy.
● Corresponding mature peptide sequence will be identified by bioinformatics
approach from this cloned biosynthetic precursor-encoding cDNA sequence.
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●Solid phase synthesis method will be used to get sufficient quantities of this peptide
in short time to evaluate its bioactivities.
●Reversed Phase-High Performance Liquid Chromatography (RP-HPLC) will be
used to remove the impurities of synthesized peptide.
● Quantitative assay of synthetic replicate of synthesized peptide will be carried out






2.1 Molecular Cloning and Sequencing
2.1.1 Acquisition of Skin Secretion from Pelophylax nigromaculatus
The method to obtain the defensive skin secretions of Pelophylax nigromaculatus
was about mild electrical stimulation. Amphibian gland secretion was induced onto
the dorsal surface using gentle transdermal electrical stimulation (5 V, 100 Hz, 140
ms pulse width) (C.F. Palmer, UK) with each stimulus lasting 10 seconds.
The resulting secretions were rinsed using a stream of distilled deionised water and
then collected in a chilled glass beaker. Finally, the liquid was frozen in liquid
nitrogen, frozen skin secretions were lyophilized using an Alpha 1-2 /LD freeze
dryer (Germany) and stored at -20°C prior to analysis until mRNA extraction.
The method described above was widely used by many research groups and caused
no harm to the experimental animals.
2.1.2 mRNA Isolation
The Dynabeads® mRNA DIRECT™ Kit (Dynal Biotech, UK) was applied for
quickly and easily isolate poly-A mRNA. The short sequences of oligo-dT were
covalently bound to Dynabeads oligo-(dT)25 and then hybridized to the poly-A tail of
the mRNA. Isolated mRNA was obtained in this method can be directly used in all
downstream applications in molecular biology.
Five mg lyophilized skin secretions of the Pelophylax nigromaculatus were placed in
1.5 ml tube, then was dissolved in 1 ml of cell lysis / binding buffer. The tube was
vortexed for 1 min and then placed on ice for 1 min in order to prevent mRNA from
degradation, and these steps were repeated five times. The tube was then centrifuged
at 18,000 × g for 5 min at room temperature to acquire a clear cell lysate. Then the
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lysate was moved to pre-washed dynabeads and it was mixed thoroughly. When the
tube was kept on the rack and until liquid became clear, all solution was discarded to
get the hybrid of beads-mRNA and all mRNA was on the beads. The mixture was
washed with 500 µl Washing Buffer A and 500 µl Washing Buffer B respectively.
Finally, we added 18 ul Elution Buffer in order to elute the mRNA from the beads
and the tube was incubated at 80°C for 2 min. Then the tube was placed onto the
magnetic rack as soon as possible to obtain the supernatant containing mRNA. The
supernatant was removed to a new PCR tube.
2.1.3 cDNA Library Construction
First strand cDNA was synthesised basing on a SMARTTM RACE cDNA
Amplification Kit (BD CLONTECH UK).
Firstly, five 0.2 ml sterilised microcentrifuge tubes were prepared (marked as
separately 3’ tube1, 3’ tube2, 3’ tube3, 5’ tube1, and 5’ tube2). Then the 5’-RACE
Ready cDNA and 3’-RACE Ready cDNA were prepared separately in 5’ tube1/2 and
3’ tube1/2/3, which were prepared as described in Table 2.1.
Table 2.1. The components of the 3’ RACE and 5’ RACE PCR
3'-RACE-Ready cDNA 5'-RACE-Ready cDNA
4 µl mRNA 3 µl mRNA
1 µl 3’-CDS primer (10 µM) 1 µl 5’-CDS primer (10 µM)
1 µl BD SMART IITM A Oligonucleotide (10
µM)
17
The mixture of each tube was mixed completely. The five tubes were briefly
centrifuged at 12,000 × g and samples were collected at the bottom of the tube. All
tubes were incubated at 70°C for 2 min and then immediately cooled on ice for 2 min.
The sample was centrifuged briefly before adding reagents that were listed in Table
2.2.
Table 2.2. The components for each reverse transcription reaction
Component Final volume Final concentration
5 × First-Strand Buffer 2 μl 1 ×
DTT 1 μl 2 mM
dNTPMix 1 μl 1 mM
BD PowerScript Reverse Transcriptase 1 μl 10 U
mRNA template 5 μl 200 ng
After all the reagents were added, the five tubes containing samples were briefly
centrifuged to have all the solution at the bottle. (Note: air bubbles should be
eliminated before being incubated) Subsequently, all tubes were incubated in a
thermal cycler at 42°C for 1.5 h. Then, 50 µl of water was added to each tube before
the five tubes were incubated the thermal cycler for 7 min at 72°C and finally stored
at -20°C.
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2.1.4 RACE Polymerase Chain Reaction (PCR)
2.1.4.1 Rapid Amplification of cDNA Ends (RACE)
The cDNA was subjected to RACE procedures to obtain open-reading frame-
encoding nucleic acid sequence data using a SMARTTM RACE cDNA Amplification
Kit (BD CLONTECH UK).
The 3’-RACE reaction employed an NUP (Nested Universal Primer) primer
(supplied with the kit) and a degenerate sense primer (5’-
ATGTTNACYTTCNAGAAATC -3’) that was designed to a highly-conserved
domain of the 5’-untranslated region of previously-characterised cDNAs encoding
precursor of Pelophylax frogs. The volume and final concentration of the
components in the RACE PCR reactions are shown in Table 2.3.
Table 2.3. Components in each tube of sample group in RACE PCR
3.1 µl PCR water
1.5 µl 10 × BD Advantage 2 PCR Buffer
0.5 µl NUP primer (20 mM)
0.5 µl 3’ sense primer/ 5’ sense primer (20 mM)
0.2 µl dNTP (10 mM)
0.2 µl 50 × BD AdvantageTM 2 Polymerase Mix
For the two tubes of the sample group, 5 µl 3’ cDNA were added into each tubes,
and for the two control group tubes, 5 µl of PCR-Grade Water were added into each
tubes. All of the reagents were pipetted completely and micro-centrifuged to collect
all contents at the bottom without bubbles. Finally, the RACR-PCR programme with
a gradient temperature was set and commenced in the thermal cycler (ThermoFisher
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Scientific, USA), choosing the ‘RACE PCR’ programme which is shown in Table
2.4. The products were stored at 4°C.
Table 2.4. The stages of the ‘RACE PCR’ programme
Stage Parameter
Stage 1 initial denaturation at 96°C for 1min
Stage 2 40 cycles (denaturation at 96℃ for 20 s, primer annealing at
55°C for 10 s, extension at 60℃ for 4 min)
Stage 3 final extension at 72°C for 10 min
2.1.4.2 Agarose Gel Electrophoresis of RACE PCR Products
In order to analyse RACE PCR products, 0.45 g agarose (Invitrogen, UK) was
transferred into a 200 ml flask with 35 ml fresh working 1 × TBE Buffer (Invitrogen,
UK). The solution was heated until the agarose was dissolved completely and cooled
at room temperature for several minutes. Then, 2.5 µl of ethidium bromide (10
mg/ml) was added to the agarose solution. Next, the melted agarose was poured into
the gel cast with one comb inserted and solidified for 40 min to make a 1.5% agarose
gel.
Subsequently, 1.5 µl of RACE PCR product was mixed with 0.5 µl of loading dye (6
× , Promega, USA). The sample mixtures and 2.5 µl 100 bp DNA ladder (0.5 µg/lane,
BioLabs, UK) were loaded to adjacent wells. The gel electrophoresis was run at 90 V
for approximately 40 min.
The gel was then transferred to a UV trans-illuminator-BioDoc-It® Imaging System
(NVP, Nuffield Road, Cambridge, UK) for analysis.
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2.1.4.3 PCR Product Purification
The product of the PCR step contained impurities such as enzymes, redundant
dNTPs, non-specific PCR products and inaccurate primers. Purification of the PCR
product was necessary for the next transcription step. The purification of RACE PCR
products was performed by use of a Cycle Pure Kit (Omega Bio-Tek, USA).
Quintuple the volume of CP buffer than that of the samples was added to the tubes
containing RACE PCR products and mixed by gently pipetting. The sample/CP
buffer mixtures were transferred to the Cartridge Filter and centrifuged at 15,000 × g
for 1 min in an Eppendorf Centrifuge 5424 (Eppendorf, Germany). The liquid was
discarded. Then the samples were washed with 500 µl and 700 µl CP washing buffer,
respectively. After centrifugation at 15,000 × g for 1 min, the effluent was discarded
and the column was transferred to an autoclaved 1.5 ml tube. Then we added 30 µl
of water to the column, hold the column for 2 min, centrifuged at 15,000 × g for 1
min, and finally discarded the column. The eluted DNA sample was dried in a
vacuum concentrator for about 40 min.
2.1.5 Recombinant Plasmid DNA
2.1.5.1 Ligation of Interested DNA with pGEM®-T Easy Vector
This step employed a pGEM®-T Easy vector system (Promega, USA).
DNA samples were resuspended in 2-8 µl PCR water and ligation reactions were set
up in PCR tubes as described in Table 2.5.
Table 2.5. Reaction components and concentrations in ligation reaction
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Reagent Volume Final concentration
2 × Rapid Ligation Buffer 2.5 µl 1 ×
pGEM®-T Easy Vector (50 ng/µl) 0.5 µl 5 ng/µl
Diluted PCR products 1.5 µl
T4 DNA Ligase (3 Unit/µl) 0.5 µl 0.3 Unit/µl
The 2 × Rapid Ligation Buffer was vortexed before each use. The reactions were
mixed by pipetting and tubes were kept for 1 h at room temperature and then stored
in the fridge at 4°C overnight.
2.1.5.2 Transformation of the Recombinant Plasmid DNA
The pGEM®-T Easy vector System (Promega, USA) was applied in transformation
as well. In transformation, unligated and recombinant plasmids were transferred into
JM109 High Efficiency E.coli competent cells (>108 CFU/µg, Promega USA) and
cultured on prepared Luria-Bertani (LB) agar Petri dishes.
The JM109 High Efficiency E.coli competent cells (>108 CFU/µg, Promega USA)
were removed from -80℃ storage and placed on ice to thaw about 4 min. A volume
of 2.3 µl of ligation products were added to a 1.5 ml tube (sterile) on the ice, then 60
µl JM109 Cells were added into the tube containing the ligation products carefully.
The contents of tubes were mixed by gently flicking then they were placed on ice for
20 min. After that the cells were heated in heating block at 42ºC for 47 seconds
(accurate time and temperature is necessary and do not shake). The tubes were then
moved onto ice immediately for 2 min. After adding 950 µl room temperature S.O.C
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medium (Invitrogen, USA), the tube was incubated for 1.5 h at 37°C with shaking
(150 × g).
One hundred and ten µl of each transformation culture was plated evenly onto
duplicate LB/Ampicillin/IPTG/X-Gal plates. The plates were then incubated
overnight (16-24 h) at 37°C. Five plates with transformation products were removed
from the incubator and blue-white screening was performed near the Bunsen burner.
The white colonies (recombinants) were easily distinguished from the blue colonies
(non-recombinants) by selecting the appropriate area and transferring it to a newly
activated plate by drawing a continuous line similar to the 'Z' with a sterile
inoculation loop on. Three prepared LB agar plates with Ampicillin / IPTG / X-Gal
were divided into a number of squares. A white colony was sampled to a square of a
plate. After all inoculations were completed, the plates were then incubated overnight
(16-24 h) at 37°C to allow these white colonies to regrow.
2.1.5.3 Isolation of Recombinant Plasmid DNA from JM109 E.coil Cells
Only pure white colonies were selected for the next cloning PCR step. Each white
colony was carefully picked using an autoclaved tip and resuspended in a
corresponding 1.5 ml PCR tube containing 20 μl of PCR-Grade Water. Placed all
tubes in a heating block at 100°C for 5 min and then immediately transferred onto ice
for 5 min.
Finally, vials were briefly vortexed and centrifuged at 20,000 × g for 5 min prior to
use. Recombinant plasmid DNA was in the supernatant which was added to new
PCR tubes and kept at -20°C.
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2.1.6 Cloning PCR
2.1.6.1 Cloning PCR of the DNA of Interest
All reagents were placed on ice to thaw and centrifuged briefly prior to use. Then
they were transferred to a tube as master mix and blended by pipetting and a brief
centrifugation. Subsequently, 47 µl of master mix was added to each PCR tube.
Isolated DNA products were centrifuged at 20,000 × g for 5 min in an Eppendorf
Centrifuge 5424 (Eppendorf, Germany) and 0.25 µl of Taq polymerase (Bioline, UK)
was added to every PCR tube at the same time. After centrifugation, 2.5 µl of
supernatant was added to the corresponding PCR tube. The cloning PCR was set up
in a 0.2 ml PCR tube with reagents described in Table 2.6.
Table 2.6. Components of each tube in cloning PCR
Reagent Volume Final concentration
5 × Cloning Buffer 10 µl 1 ×
dNTP Mix (10 mM) 1 µl 0.2 mM
M13F (20 µM) 2.5 µl 1 µM
M13R (20 µM) 2.5 µl 1 µM
PCR-Grade water 31 µl
Taq polymerase (5 Unit/µl) 0.25 µl 0.025 Unit/µl
DNA supernatant 2.5 µl
After all components were prepared, these PCR tubes were centrifuged briefly before
putting into the PCR machine. Then, these tubes were incubated in a 96 well
Thermal Cycler (ThermoFisher Scientific, USA), selecting the ‘Cloning PCR’
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programme as shown in Table 2.7. The cloning PCR products were stored at 4°C
prior to use.
Table 2.7. The stages of the ‘Cloning PCR’ programme
Stage Parameter
Stage 1 initial denaturation at 94°C for 1 min
Stage 2 31 cycles (denaturation at 94°C for 30 s, annealing at 55°C for 30 s,
extension at 72°C for 3 min )
Stage 3 final extension at 72°C for 3 min
2.1.6.2 Agarose Gel Electrophoresis of Cloning PCR Products
Gel analysis and purification of cloned PCR products were performed as described
before in section 2.1.4.2, but without the need to concentrate the purified products.
2.1.6.3 Purification of Cloning PCR Products
The purification of Cloning PCR products was performed by use of a Cycle Pure Kit
(Omega Bio-Tek, USA).
The details were described in 2.1.4.3.
2.1.7 DNA Sequencing
2.1.7.1 Sequencing Reaction
DNA sequencing was carried out by using a Big Dye® Terminator v 3.1 Cycle
Sequencing Kit (Applied Biosystems, USA). For the sequencing reaction, the
sequencing Master Mix was prepared in advance and 18.5 µl of the mixture was
mixed with 2.5 µl of each purified DNA product. The sequencing reaction was set up
in 0.2 ml PCR tubes. The components of each PCR tube are shown in Table 2.8.
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Table 2.8. Components in each sequencing reaction tube
Reagents Volume Initial concentration
PCR-Grade water 12.4 µl
Diluted M13F or M13R 1.14 µl 3.2 µM
2.5 × Ready reaction mix 2.86 µl 2.5 ×
5 × Big Dye Sequencing Buffer 3.57 µl 5 ×
Purified cloned PCR products 2.70 µl
After this, all the tubes were subjected to a thermal cycler and the sequencing
reaction PCR programme was as shown in Table 2.9.
Table 2.9. The sequencing reaction PCR programme
Stage Parameter
Stage 1 initial denaturation at 96°C for 1 min
Stage 2 26 cycles (denaturation at 96°C for 20 s, annealing at 55°C for 10
s, extension at 60°C for 4 min )
Stage 3 preservation at 4°C for 7 min
2.1.7.2 Purification of Extension Products
Ten microlitres of deionised water were added to each fresh 1.5 ml tube first, and 72
µl of 95% ethanol (Sigma-Aldrich, USA) were added to the tubes containing DNA
sample, followed by being transferred together with extension products to the 1.5 ml
tubes. These tubes were then vortexed for 30 s and placed at room temperature for 20
min, after which they were centrifuged at 14,000 × g for 20 min, and the supernatants
were discarded immediately. Next, 260 µl of 70% ethanol was added into the tubes
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and the tubes were vortexed for 30 s, then centrifuged at 14,000 × g for another 10
min. The supernatant was discarded quickly and the redundant liquid in the pellet
was evaporated in a concentrator for at least 3 h to generate the dried DNA fragments.
The products were then stored at room temperature.
2.1.7.3 Sanger Sequencing
First, all samples were dried in the concentrator for 45 min to completely remove the
ethanol prior to sequencing. Each tube containing the dried DNA fragment was
added 10.3 μl of HiDi (highly deionized formamide). These tubes were then vortexed
for 30 s, briefly centrifuged and placed in a heating block at 95°C for 4.5 min and
then cooled on ice for 3 min. Then we transferred 10 μl of each sample to a 96-well
sequencing plate and centrifuge tubes briefly. Finally, the DNA was sequenced by
ABI 3730 automated sequencer (Applied Biosystems, USA).
2.2 Solid Phase Peptide Synthesis (SPPS)
Solid phase peptides synthesis (SPPS) was a standard method to produce replicates
of biologically-active peptides, producing peptides in high yield (typically around
70 %) in a user-friendly manner. The peptides were synthesised from the C-terminal
to the N-terminal, although they were synthesised in the opposite direction in cells
from the N-terminal to the C-terminal. In this method, resin (Wang resin / Rink
amide MBHA resin) was used to protect the C-terminal and adopted Fmoc (9-
fluorenyl methoxycarbonyl) to protect the N-terminal. The cycle consisted
deprotection, coupling, cleavage, washing (Figure 2.1) and this four steps were
repeated to achieve the desired length of the synthetic peptide chain.
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Figure 2.1. Fmoc solid-phase peptide synthesis scheme
(http://www.sigmaaldrich.com/technical-documents/articles/biology/solid-phase-
synthesis.html)
2.2.1 Calculating and Weighting
The desired quantity of peptide was 0.15 mmol, thus each amino acid should be at
least 4 fold molar excess, thus 0.6 mmol of each amino acid were weighed into
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amino acid vials to synthesise the sequence. Correspondingly, 2-(1H-Benzotriazol-1-
YL)-1,1,3,3-Tetramethyluronium Hexafluorophosphate (HBTU) was used at the
same ratio for catalysing each coupling reaction of amino acid. The amino acids with
different protecting groups were weighed based on the sequence, and loaded into pre-
cleaned vials containing HBTU. According to its loading capacity, a 30 ml reaction
vessel was used to contain the MBHA resin. And the weight of resin was calculated
by the formula:
resin (g) = peptide (mmol) / loading capacity (mmol/g)
The sequences of amino acid for synthesis were marked from C-terminal to N-
terminal.
2.2.2 Prepared the Stock Solution in the Solvent Bottles
All the stock solution should be prepared in advanced. In solvent bottle 1 and 2, were
filled with four liters of Dimethylformamide (DMF) (SIGMA-ALDRICH, 99%)
which would be used to wash the resin between coupling and deprotection steps. In
addition, the agent in bottle 1 would be used to rinse the amino acid vials after the
activated amino acid has been transferred from the carousel to the reaction vessel.
One L of 20% piperidine (SIGMA-ALDRICH, 99%) in DMF (v/v) was moved into
the bottle 3, which was used to remove the protecting group from the N-terminal of
the growing peptide chain and to provide an activated amino acid for the following
coupling. Besides, 1 L of 11% N-Methylmorpholine (NMM) (SIGMA-ALDRICH,
99%) in 89% DMF (v/v) was transferred into the solvent bottle 4. In this reagent,
carboxyl-activated amino acid from the vial would be activated and then the coupling
reaction would occur to expand the peptide chain fixed on the resin. In the solvent
bottle 4, it was filled with 1 L of Dicholormethane (DCM) (SIGMA-ALDRICH,
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99%), which would be used for bubbling step in order to remove the remaining DMF
and other soluble impurity.
2.2.3 Peptide Synthesizing by Tribute Synthesizer
The Tribute Peptide Synthesizer was used to accomplish the peptide synthesis. The
Peptide Synthesiser was started using the programme shown in Table 2.10 below.
Table 2.10. Programme used for single coupling in SPPS. The synthesis loop is
from step 2-step 8
No. Action Bottle Time Repeat Comments
1 RV-Top 1 10 min 3
DMF environment
(first AA only)
2 RV-Top 3 150 s 3 Deprotection
3 Wash 1 30 s 1 Remove piperidine
4 RV-Top 1 30 s 3
Wash resin
(remove piperidine and Fmoc)
5 AA-Delivery 4 Activation
6 Mix 25 min Coupling
7 Wash 1 30 s 1 Remove NMM
8 RV-Top 1 30 s 3 DMF environment
9 RV-Top 3 150 s 3 Final deprotection (last AA only)
10 Wash 1 30 s 1 Wash vent (last AA only)
11 RV-Top 1 30 s 3 Wash resin (last AA only)
12 RV-Top 5 30 s 3
Bubbling and remove DMF
(last AA only)
13 Drain-Dry 10 min (last AA only)
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2.2.4 Cleavage and Deprotection of Peptide
Those amino acids vials and the reaction vessel were taken out of the machine when
all programs were finished. The peptide-resin powder in reaction vessel was
transferred to a 50 ml round-bottomed flask after being weighed out. Then the
cleavage mixture was prepared and added in the 50 ml round-bottomed flask with
peptide-resin powder.
Reagents in the cleavage mixture: 94% Trifluoroacetic Acid (TFA) + 2%
Ethanedithiol (EDT) + 2% Triisopropylsilane (TIS) + 2% H2O
The cleavage reaction was performed with stirring at room temperature in an air
chamber for 2 h. Then the cleavage mixture was filtrated and transferred into a new
50 ml round-bottomed flask. The new 50 ml round-bottomed flask was fitted on
Rotary evaporator at 40°C for drying. Resting solution was transferred into a 50 ml
tube when the volume of solution in a flask was around 5 ml. Forty-five ml Et2O
(diethyl ether) was added in the tube with resting solution and refrigerated at -20°C
overnight to precipitate synthetic peptide.
2.2.5 Washing and Lyophilisation
Until all peptide was dissolved in 45 ml of cold diethyl ether. Then it was centrifuged
in order to collect the peptide and all liquid was discarded carefully. And about 45 ml
of cold diethyl ether was added into the peptide again. These steps were repeated for
3 times.
When all peptide was dissolved in 10 ml of Buffer B (80% acetonitrile + 19.5% H2O
+ 0.5% TFA), the peptide solution was frozen in -57°C liquid nitrogen first and then
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it was lyophilised under vacuum. Finally, the dry peptide was store at -20°C prior to
purification.
2.3 Peptide Purification by RP-HPLC
The separation and purification of the synthesized peptide was achieved by Cecil
Adept CE4200 high performance liquid chromatography HPLC system (Amersham
Biosciences) and controlled by Powerstream HPLC software.
The HPLC buffer A/B which were mobile phase in the system were prepared prior to
use. The components of HPLC buffer A/B were below:
 Buffer A (trifluoroacetic acid (TFA)/water (0.05/99.95, v/v))
 Buffer B (trifluoroacetic acid (TFA)/water/acetonitrile (0.05/19.95/80.00,
v/v/v))
HPLC buffer B was degassed in the ultrasound bath (Fisher Scientific, FB 15049) for
20 min prior to use.
Before the sample injection, the column was washed with Buffer B (TFA/ ddWater/
Acetonitrile, 0.05/19.95/80.00, v/v/v) for 30 min and then it was equilibrated with
Buffer A (TFA/ddWater, 0.05/99.95, v/v) for another 40 min.
Two milligram of lyophilised peptide was reconstituted in 1 ml 3:2 HPLC Buffer
A/B mixed solution clarified by centrifugation for 15 min at maximum speed. After
sample injection, the separation was performed under a gradient elution from 100%
Buffer A to 100% Buffer B in a Jupiter C-5 semi preparative column (Phenomenex
C-5 column, 0.46 cm × 25 cm, U.K). Separation of the sample was performed over
80 min at a flow rate of 1 ml/min and the effluent was constantly monitored by a UV
detector set at 214 nm (λ) in order to detect the peptide bonds. The fractions were
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collected once the peaks were shown and the tubes were labelled with the
corresponding time.
2.4 MALDI-TOF Mass Spectrometry Analysis
A MALDI-TOF mass spectrometer (Voyager DE, PerSeptive Biosystems,
Framingham, MA, USA) was used for mass analysis.
A volume of 2 ul of HPLC fraction was loaded and spotted into a well of MALDI-
TOF plate, then α-cyano-4-hydroxycinnamic acid (CHCA) was added to the spot of
each sample and left to dry and it was prepared as 10 mg/ml solution of CHCA in
acetonitrile/TFA/Water (50/0.05/49.95, v/v/v). The fractions from HPLC were
analysed by MALDI-TOF/MS with CHCA as the matrix in positive mode. The
instrument was calibrated by standards and set accuracy was ± 0.1%. Masses were
recorded based on mass to charge ratio (m/z) and the masses observed were
compared with the theoretical mass values that had been calculated earlier.
According to each fraction mass, a certain fraction from HPLC would be matched to
QUB-1804. These fractions were lyophilized and stored at -20°C prior to further
bioactive analysis.
2.5 Bioactive Assays
2.5.1 Trypsin Inhibitory Assay
The trypsin stock solution was prepared by using 1 mmol/L HCL solution and trypsin
powder. The concentration was 1 mM. The solution was stored at -20°C. And the
substrate used in this experiment was Z-Gly-Gly-Arg 7-amino-4-methylcoumarin
hydrochloride. The substrate of 6.16 mg was dissolved in 1 ml dimethylformamide
(DMF) to prepare the substrate stock solution. Then it was stored at -20°C. Then
prepared 1000 µM peptide solution and diluted to 100 µM, 10 µM and 1 µM. Used
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10 µL 1 mM trypsin stock solution was diluted by 9.99 ml 1 mM HCl solution to 1
µM trypsin working solution. Then, 50 µl substrate stock solution was diluted by
9.95 ml PBS and 180 µl substrate was added into the wells of a black 96-well plate.
The layout and the solutions added can be seen as following:
Blank Negative Control Samples










































*Concentration of peptide added, A5-A12: 1000 µM, B5-B12: 100 µM, C5-C12: 10 µM, D5-D12: 1
µM
2.5.2 Antimicrobial Assay
Antimicrobial assays were carried out to detect the MICs and MBCs against a Gram-
positive bacterium, a Gram-negative bacterium, and a yeast, respectively.
Staphylococcus aureus (S.aureus) (NCTC 10788), Escherichia coli (E.coli) (NCTC
10418) and Candida albicans (C.albicans) (NCPF 1467) were stored at the -20°C
freezer. The culture beads were incubated in Mueller-Hinton Broth (MHB) overnight
(16-20 h) in a shaking incubator at 37°C.
Five hundred ul of the overnight growth cultures were moved to 20 ml McCartney
bottles of MHB and incubated in the shaking incubator until logarithmic phases of
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growth were achieved as assessed by the optical density (OD) of the cultures at
λ=550 nm.
Organism Subculture time OD Concentration(CFU/ml)
S.aureus 1.5 h 0.23 1.0 × 108
E.coli 1.0 h 0.41 1.0 × 108
C.albicans 1.0 h 0.15 5.0 × 106
The cultures were subjected to dilution to obtain 5 × 106 colony-forming units
(cfu)/mL for bacteria or yeast.
2.5.2.1 Minimum Inhibitory Concentration (MIC) Assays
Serial peptide dilutions and cultures were loaded into a 96-well microtiter plate with
suspensions containing 1-512 µM of the tested peptides with 5 replications. The 96-
well microtiter plate was incubated at 37°C overnight.
MICs values were determined as the lowest concentrations which produced a similar
OD value detected by the Synergy HT plate reader (BioTek, USA) at 550 nm
compared to the negative control (medium only).
2.5.2.2 Minimum Bactericidal Concentration (MBC) Assays
The inhibited cultures of 20 µl on the 96 plate were sub-cultured on the MHA plate
and incubated overnight at 37°C. The MBC was the lowest concentration with no
bacterial growth.
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2.5.3 Anticancer Cell Activity Assay
2.5.3.1 Resuscitation of Frozen Cell Lines
The cell lines used for this bioassay included PC-3, MCF-7, NCI-H157 and
U251MG. The medium used for cell resuscitation contained foetal bovine serum
(FBS) (Sigma-Aldrich, USA) and penicillin-streptomycin (P-S) (Sigma-Aldrich,
USA). The final concentrations of FBS, penicillin and streptomycin in the medium
were 10%, 100 Units/ml and 100 μg/ml respectively. First, 15 ml of medium was
transferred to a medium-sized culture flask (Sigma-Aldrich, USA). The frozen cells
were taken out of a -80°C freezer and swiftly stirred in a pre-warmed 37°C water
bath to defrost immediately. After this, all cells were transferred into a 75 cm2
culture flask with pre-warmed 15 ml culture medium. The flask was shaken gently to
mix medium and cells thoroughly and swayed gently to dilute cryoprotectant DMSO.
Finally, the flask was placed in an incubator at 37°C containing with 5% CO2.
2.5.3.2 Cell Subculture and Passage
Initially the spent culture medium was discarded after the cell check, then added 10
ml of pre-warmed PBS solution to the flask and shaked gently to wash the cells.
Thereafter, 1000 μl of 1 × Trypsin / EDTA solution was added to culture flask
containing 10% FBS without Ca2+ and Mg2+, and the flask was then incubated for
about 2 min to digest and separate the cells adhered on the surface of the flask.
Subsequently, 10 ml of pre-warmed medium was added to the above flask and
pipetted to stop the digestion, followed by cell aspiration. Afterwards, all cell
suspensions were transferred to 15 ml universal tubes and centrifuged at 200 × g for
5 min. The supernatants were discarded and 5 ml of pre-warmed medium was added
to a 15 ml universal tube and mixed thoroughly with the cells. Finally, 2 ml of the
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cell suspension was transferred to a new 75 cm2 culture flask with 15 ml of pre-
warmed medium and then incubated at 37°C in a humidified environment containing
5% CO2 after cell examination. In addition, harvested cells can be used for
cryopreservation of cell lines, MTT assay, or serial passaging after the first passaging.
2.5.3.3 Cell Quantification
MTT cell viability assay was performed when secondary passage cells covered 90%
of the surface of the flask. The AS1000 Modified Hemocytometer (Hawksley, UK)
was used here for cell quantification. Added 7 ml of pre-warmed medium to
thoroughly aspirate cells and resuspended the cells. Afterwards, 50 ul of cell
suspension was mixed with an equal volume of Trypan Blue and then loaded onto
the hemocytometer. Observed the distribution of the cells under a microscope.
Counted the successfully-stained (dead) cells in a specific chamber with the aid of a
counter. All cells existing in the culture can be quantified according to the formula:
The number of cells = n/m × D ×104. [n = the number of counted cells; m = the
number of grids; D = 2 (dilution factor)]
2.5.3.4 Cell Seeding
An appropriate volume of cell suspension and pre-warmed medium were mixed and
diluted to 5000 cells/100 μl (for each well) with the medium. A 96-well plate was
required and 100 μl samples of cell suspension were seeded in each well. Afterwards,
the 96-well plate was placed in an incubator at 37°C under 5% CO2 overnight.
37
2.5.3.5 Cell Starvation
The medium in the 96-well plate was discarded using a pipette. One hundred ul of
pre-warmed FBS-free medium was added to each well and the 96-well plate was
replaced into the 37°C incubator under 5% CO2 in humidified atmosphere for 6-12 h.
2.5.3.6 Peptide Preparation
Five mg of peptide QUB-1804 was weighed and dissolved in 230 μl DMSO to
prepare a stock solution in the concentration of 10-2 M. Then 60 μl of the stock
solution was 10-fold diluted in 540 μl of pre-warmed FBS-free medium to achieve a
range of concentrations from 10-3M to 10-9M.
2.5.3.7 Peptide loading
After removing all media, 100 ul of each dilution of peptide in each concentration
was loaded into each well of 96-well plate in 5 replicates. One hundred μl of pre-
warmed FBS-free medium was used as a positive control and an equal volume of 1%
DMSO solution was also added as a vehicle control which reflected the effect of 1%
DMSO on cell growth. Finally, the 96-well plate was incubated for 24 hours at 37 °C
in a humidified environment with 5% CO2.
2.5.3.8 MTT assay
Yellow-coloured MTT solution (5 mg/mL) (Sigma, UK) of 10 ul were added into
each well in a dark environment and incubated for about 4-6 h. When the
supernatants were discarded completely by use of a syringe, 100 μL of DMSO were
added into each well quickly followed by gentle agitation in the orbital incubator
(Stuart, UK) for 10 min to dissolve the insoluble purple formazan crystals. Finally,
the absorbance of the coloured solution was measured at 570 nm using the Synergy
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HT plate reader (BioTek, Winooski, VT, USA). The statistical results were analysed
by t-test through GraphPad Prism 6.0 software. A p value of < 0.05 was considered
statistically significant.
2.5.4 Haemolysis assay
2.5.4.1 Horse blood preparation
Two ml of fresh defibrinated horse blood (TCS Biosciences Ltd, Buckingham, UK)
were added into a 50 ml universal tube and centrifuged at 930 × g for 5 min. Then,
the cloudy supernatants were discarded completely and 30 ml of PBS solution were
added. Several washing steps were repeated until the supernatants were clear. Then,
the supernatants were discarded as cleanly as possible and PBS solution was refilled
to the 50 ml volume. Finally, gentle shaking was required to obtain an even 4% (v/v)
erythrocyte suspension.
2.5.4.2 Calculations and peptide dilution
Peptide was dissolved in sterilised PBS which were used to make peptide solutions at
different concentrations: 512 µM, 256 µM, 128 µM, 64 µM, 32 µM, 16 µM, 8 µM, 4
µM, 2 µM and 1 µM. For each concentration, 200 μl of peptide solution were added
into a 1.5 ml tube and there were 5 replicates for each concentration. Finally, 200 μl
of red cell suspension were added into each tube.
The blank group was prepared with 4 ml of red cell suspension. In addition, 40 μl of
Triton X-100 was added into 1960 μl of PBS and then 2000 μl of red cell suspension
was also mixed in to serve as a positive control. All the tubes were incubated at 37°C
for 2 h and then centrifuged at 900 × g for 5 min.
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2.5.4.3 96-well-plate haemolysis assay
Supernatants were added into wells of a 96-well-plate (ThermoFisher Scientific) and
the absorbance was detected at λ=570 nm with Synergy HT plate reader. The data





3.1 Molecular cloning of peptide QUB-1804 precursor encoding cDNA
The cDNA encoding the prepropeptide precursor of QUB-1804 was successfully
cloned using ‘shotgun’ cloning strategy from the cDNA library of skin secretion of
Pelophylax nigromaculatus. The translated open-reading frame amino acid sequence
of QUB-1804 precursor is as shown in Figure 3.1. More specific, the corresponding
translated open-reading frame amino acid sequence of QUB-1804, containing 63
amino acid residues. The mature peptide followed by Gly-Lys (G-K) amino residues,
which means C-terminus was subjected to opst-translational modification (PTM)
with carboxyl-terminal amide formation. The mature peptide of QUB-1804 consists
of 17 amino acid residues (GAPKGCWTKSYPPKPCS-amide). A BLAST search in
the National Center for Biotechnological Information (NBCI) database indicates that
this full-length biosynthetic precursor-encoding cDNA has high degree of identity to
ranacyclin-HB1 and ranacyclin-HB2 (Figure 3.2A). As for the translated open-
reading frame amino acid sequence (Figure 3.2B), they all contain 63 amino acid
residues, composed of signal peptide sequence, acidic spacer peptide sequence,
mature peptide sequence (17 amino-acid in length), a conventional enzymatic
processing dibasic peptide domain, Lys-Arg (-KR-) at position 42 and 43 which
plays a key role for the enzymatic cleavage of N-terminus of the mature peptide and
C-terminal amide contributed by Gly-Lys (G-K) amino residues at position 61 and
62. Their mature peptide squences are of highly similarity with only three different
amino acids at position 46, 57 and 60. Taken together, identifying the bioactive
peptide, QUB-1804, form this transcripts (Figure 3.1 and Figure 3.2) is reasonable.
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Figure 3.1. Nucleotide and translated open-reading frame amino acid sequence of
precursor cDNA of QUB-1804. The open-reading frame consists of 63 amino acid
residues. The putative signal peptide sequence is double-underlined, the following
spacer peptide sequence ends with a -KR- cleavage site, the mature peptide sequence




Figure 3.2. (A) The significant alignment of the translated open-reading frame
amino acid sequence of precursor cDNA analysed by NCBI protein BLAST. This
full-length biosynthetic precursor-encoding cDNA has high degree of identity to
ranacyclin-HB1 and ranacyclin-HB2. (B) The corresponding DNA sequence
encoding precursor peptides of QUB-1804, ranacyclin-HB1 and ranacyclin-HB2
respectively. The symbol ‘*’ indicates they have the same nucleotide acids sequence,
the symbol ‘:’ indicates similar blocks.
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3.2 RP-HPLC chromatography analysis and MALDI-TOF molecular weight
determination of the crude synthetic peptide QUB-1804
Through the MALDI-TOF analysis, the observed molecular mass of the synthetic
peptide is 1805.7, which is consistent with the computational mass of QUB-1804,
indicating the success of solid peptide synthesis (Figure 3.3). A 2 Da less of the
observed peptide mass in the MALDI-TOF MS spectrum confirms the formation of
disulfide bridge between the two cysteine in the peptide sequence. The following RP-
HPLC chromatogram proves a relative high degree of purity of synthetic QUB-1804
by observing single peak containing the desired peptide molecule (shown by arrow in
Figure 3.4). The retention time of QUB-1804 is 38 min. The further purification by
RP-HPLC of QUB-1804 was conducted to remove the impurities and the collected
fractions were subjected to biological assays after lyophilisation.
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Figure 3.3.MALDI-TOF spectrum of the crude synthesized peptide QUB-1804. The mass of singly-charged ion [M+H]+ of QUB-1804 is 1805.7
Da. The masses of sodium and potassium adduct ions ([M+Na]+ and [M+K]+) are shown as 1828.27 and 1844.62, respectively.
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Figure 3.4. The full chromatogram of the synthetic peptide QUB-1804 using RP-HPLC in a run time of 80 min. The retention time of QUB-1804
is 38 min and the fraction containing QUB-1804 is indicated by arrow.
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3.3 Physicochemical properties and secondary structure prediction of QUB-
1804
The physiochemical properties of QUB-1804 (Figure 3.5) were determined using
online protein/peptide analysis tool, Heliquest web server (Gautier et al., 2008).
QUB-1804 has 3 net positive charge, contributed by a charged residue (Lys 3). The
primary structure contains 9 nonpolar residues (about 53%) and 8 polar residues
(about 47%). The hydrophobicity of OUB-1804 is 0.394 and the hydrophobic
moment of is 0.051. The secondary structure prediction of QUB-1804 was
determined by I-TASSER (Yang et al., 2015) and the result is shown in Figure 3.6.
The secondary structure of QUB-1804 was composed of coil conformation rather
than α-helicity and strand.
Figure 3.5. The physiochemical properties of peptide QUB-1804. QUB-1804 has 3
net positive charge. The primary structure contains 9 nonpolar residues and 8 polar
residues. The hydrophobicity of OUB-1804 is 0.394. The hydrophobic moment of
QUB-1804 is 0.051.
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Figure 3.6. The secondary structure predicted by I-TASSER. H, S and C represent
for helix, strand and coil respectively.
3.4 Trypsin Inhibitor Activity of QUB-1804
The trypsin inhibitor assay employed the trypsin hydrolysis related fluorogenic
substrates in the treatment of a series concentrations of QUB-1804 from 0.02381 to
9.524 µM in two-fold dilution. The kinetic curve of the fluorophore-release progress
is well differentiated in Figure 3.7. The high concentration of QUB-1804
significantly inhibit the trypsin hydrolysis within 240 min. The further calculation of
Ki value was conducted using Morrison equation (Figure 3.8), and Ki value of QUB-
1804 is 0.373 µM. The low velocity of trypsin activity treated with QUB-1804
indicated that the tested peptide had relatively strong trypsin inhibitory activity.
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Figure 3.7. The kinetic curves of trypsin proteolysis in the presence of different concentrations of QUB-1804 for 240 min. Each concentration
has two replicates and indicated by the different color.
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Figure 3.8. The velocity plot of trypsin hydrolysis in the treatment of QUB-1804.
The Ki of QUB-1804 is 0.373 µM using Morrison equation. Km = 71.95 µM, [S] =
42.86 µM, Et = 0.002 µM.
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3.5 Antimicrobial Activity of QUB-1804
In the minimum inhibitory concentration assay, QUB-1804 does not exhibit any
antimicrobial activity against the growth of a Gram-positive bacterium
Staphylococcus aureus, a Gram-negative bacterium Escherichia coli and a yeast,
Candida albicans up to the concentration of 512 µM (Figure 3.9).
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Figure 3.9. The antimicrobial activity of QUB-1804 against S.aureus (A), E.coli (B)
and C.albicans (C). The microorganisms were tested using QUB-1804 at the
concentrations from 512 µM to 1 µM. The cell survival rate at each concentration is
close to 100%, which indicated that QUB-1804 have no effects against the three
model bacterial.
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3.6 MTT cell proliferation assay of QUB-1804
Four human cancer cell lines, including human prostate carcinoma cell line (PC-3),
the non-small cell lung cancer cell line (H157), human glioblastoma astrocytoma
(U251MG) and the human breast cancer cell line (MCF-7), were subjected to MTT
screening in the treatment of 10 µM of QUB-1804. Compared to the growth control
group, QUB-1804 is not able to inhibit the proliferation of those cancer cell lines at
10 µM within 24 h (Figure3.10).
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Figure 3.10. The anti-proliferation effect of QUB-1804 on MCF-7 (A), PC-3 (B),
U251MG (C), and H157 (D). The percentage of cell viability in the treatment of 10
µM of QUB-1804 was compared that of growth control. Five replicates were
conducted for each experiment and the error bars present the SD of those replicates.
The significance of data was performed using t-test, and ‘ns’ means no significance
between two groups.
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3.7 Haemolytic Activity of QUB-1804
The haemoglobin release in the plasma determines the haemolytic activity.
Measurement of optical density at the wavelength of 550nm can evaluate red blood
cell lysis. As shown in Figure 3.11, QUB-1804 exhibits a low haemolytic activity
from the concentration of 256 µM to 1 µM. Whilst QUB-1804 induced 27%
haemolysis at the highest concentration of 512 µM. When the concentration lower
than 256 µM, it shows that there is no significant haemolysis. The haemolysis of
QUB-1804 at the concentration of corresponding Ki against trypsin is negligible. The
negative and positive control consist of PBS and 1% Triton X-100, respectively.
Figure 3.11. Haemolytic activity of QUB-1804 following incubation with horse red
blood cell for 2 h. The highest haemolysis is 27% at high peptide concentration of







Protease inhibitors are widely distributed in plants, animals and microorganisms
(Christeller, 2005, Joanitti et al., 2006). Serine proteases and their related inhibitors
have been studied in the most detail. They are of broad interest because they perform
some key roles in fundamental processes such as blood coagulation, inflammation,
complement fixation and peptide hormone release, meanwhile, they constitute
pathogenic factors in some diseases including cancer, inflammation, fibrinolysis and
pulmonary emphysema (Ivanov et al., 2006, Drag and Salvesen, 2010). As a
promising resource of amphibian skin secretion, serine protease inhibitory peptides
have been discovered and shown conservative reaction-loop structures, which are
related to Kazal, Kunitz and Bowman-Birk inhibitor families (Laskowski Jr and Kato,
1980, Bode and Huber, 1992).
In this study, we described a trypsin inhibitor, QUB-1804, that was discovered from
skin secretion of Pelophylax nigromaculatus, by molecular cloning of its cDNA
encoding precursor. After which the peptide was synthesised by solid phase peptide
synthesis, it was purified by high performance liquid chromatography. Finally, we
did some functional assays including trypsin inhibition assay, antimicrobial assay,
MTT cell proliferation assay and haemolysis assay.
All Bowman-Birk-type protease inhibitors show a classical highly-conserved
disulphide-bridged reactive center loop: -C-T/A-X-S/A-X-P-P/A-X-C- (Laskowski Jr
and Kato, 1980, Wang et al., 2012b). The primary structure of QUB-1804 is
GAPKGCWTKSYPPKPCS-amide, which contains a typical Bowman Birk-type
protease inhibitor loop between Cys6 and Cys16, so QUB-1804 could be considered as
belonging to Bowman-Birk-type inhibitor family. Hovewer, QUB-1804 contains 11-
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residue loop with two additional residues at the first and the last position inside the
disulphide reactive loop, which are Trp7 and Pro15. The primary structural feature of
QUB-1804 is compared with other three peptides belonging to ranacyclin family
(Table 4.1) which were search from NCBI BLAST. QUB-1804 has high degree of
identity to ranacyclin-HB1, ranacyclin-HB2 and ranacyclin-N, therefore, QUB-1804
is a Bowman-Birk-type protease inhibitor which belongs to ranacyclin family.







Many publications reported that trypsin can cleave peptide bonds that are specifically
at C-terminal side of lysyl (K) and arginyl (R) residues, except when the following
amino acid is proline residue (Olsen et al., 2004). Their function is achieved by
binding in a substrate-like way to their cognate enzyme, forming a stable complex.
Many Bowman-Birk-type inhibitors with Arg (R) or Lys (K) at the position P1 tend
to inhibit trypsin and other trypsin-like enzymes, while the P1 position with Leu, Met,
Tyr, Phe or Trp are likely to inhibit chymotrypsin and chymotrypsin-like enzymes
(Odani and Ono, 1980, McBride and Leatherbrrow, 2001). Various semi-synthesis
BBI proteins are generated, and they have shown that Arg (R) and Lys (K) are the
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optimal P1 position for trypsin inhibition while Phe (F) residue is preferred in the P1
position to inhibit chymotrypsin (Odani and Ono, 1980). In the project conducted by
Lin et al. (Lin et al., 2016), they synthesized a Bowman-Birk- type inhibitor named
pLR-HL in which the P1 position is Lys8, and they substituted Lys8 with Phe8 at P1
position. The result is in anticipation, pLR-HL exhibited strong trypsin inhibitory
activity with a Ki value of 0.143 µM without chymotrypsin inhibitory activity. Phe8-
pLR-HL devoid of trypsin inhibitory activity while it exhibited chymotrypsin
inhibitory activity with a Ki value of 2.141 µM. In this study, the reactive site (P1)
residue of QUB-1804 is Lys9, in expectation, QUB-1804 exhibits trypsin inhibitory
activity with a Ki value of 0.373 µM. However, it shows no inhibition effect on
chymotrypsin.
Here, the results of antimicrobial assay indicated that QUB-1804 do not possess
significant antimicrobial activity on three model micro-organisms: Gram-positive
bacterium (S.aureus), Gram-negative bacterium (E.coli) and an opportunistic yeast
bacterium (C.albicans). These results are out of our expectation because the initial
study of this peptide, ranacyclin, were carried out on the evaluation of the
antimicrobial activity (Mangoni et al., 2003). In the study conducted by Yan, et al.
(Yan et al., 2012) identified that ranacylin-B like peptides are bi-functional
molecules with both antimicrobial activity and trypsin inhibitory activity. Another
study conducted by Li, et al. (Li et al., 2007) demonstrated that ORB, which is the
typical member of ranacyclin family, has antimicrobial activity as well as trypsin
inhibitor activity. Although the mature peptide sequence of ORB and QUB-1804 are
similar, possessing disulphide-bridged loop, QUB-1804 is not able to inhibit the
growth of tested microorganisms up to the concentration of 512 µM. QUB-1804 has
net charge of +3 while ORB has that of +5. It is speculated that the increase of net
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charge might enhance antimicrobial activity without considerably altering the trypsin
inhibitory efficacy (Powers and Hancock, 2003). Additionally, the secondary
structure of QUB-1804 was predicted by online tool named I-TASSER (Yang et al.,
2015) and the result indicated that QUB-1804 do not have any α-helix content, which
is widely considered as an important role for the lytic activity of antimicrobial
peptides (Powers and Hancock, 2003). Therefore, that QUB-1804 does not have any
helicity maybe the probable reason for the lack of antimicrobial activity.
Bowman-Birk protease inhibitor also has an important effect on preventing or
suppressing carcinogenesis, such as those of colon, breast and prostate cancers
(Kennedy, 1998). BBI has been studied extensively as an anticarcinogenesis agent
(Ekrami et al., 1993). The mechanism of this function is that these agents inhibit
hydrogen peroxide and superoxide anion radicals to release from polymorphonuclear
leukocytes and other cell types stimulated with tumour promoters (Kennedy, 1998).
In terms of anticancer property of QUB-1804, MTT assay was using four human
cancer cell lines, including PC-3, H157, U251MG, and MCF-7. The results of MCF-
7, PC-3, H157 and U251G human cancer cell lines were all negative which means
QUB-1804 exhibited no significantly anticancer activity. Recently, a research has
reported that the proteasome inhibition of chymotrypsin-like maybe the reason of the
anti-carcinogenic function of some BBI peptides (Almond and Cohen, 2002, Parlati
et al., 2009). Therefore, QUB-1804 failed to inhibit the proliferation of cancer cell
due to the lack of chymotrypsin inhibitory activity.
We also conducted haemolysis assay in order to detect the toxicity of QUB-1804.
The peptide only showed 27% haemolysis at the concentration of 512 µM. While
when the concentration is lower than 256 µM, there is no significant haemolysis. The
reason would be similar to the case of antimicrobial activity, which is no α-helical
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As we already tested, QUB-1804 has relatively strong trypsin inhibitory activity with
the Ki value of 0.373 µM. But it does not possess any antimicrobial activity on three
model microorganisms (E.coli, C.albicans, S.aureus) maybe because the lack of
cationicity and helicity. Future studies can focus on the development of bifunctional
peptides with trypsin inhibitor activity as well as antimicrobial activity based on the
classical highly-conserved disulphide-bridged reactive site loop. The analogues that
possess anticarcinogenic effects without influencing the low haemolysis could be
designed. Moreover, the biological function of QUB-1804 might not be fully
investigated, so more experiment, such as the immune response of inflammation,
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